Overview

Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

Status:
RECRUITING
Trial end date:
2027-12-30
Target enrollment:
Participant gender:
Summary
Phase 1/2, open-label study of ETX-636 in participants with advanced solid tumors
Phase:
PHASE1
Details
Lead Sponsor:
Ensem Therapeutics
Treatments:
Fulvestrant